New Biomarker Holds Promise For Monitoring Heart Disease, Baylor Health Care System Study

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Aspecial newly discovered biomarker, "Gb3," potentially related to the survival of heart disease patients, could change the way the country's No. 1 killer is monitored in the future, according to research published in the Feb. 4 edition of the Journal of the American Heart Association (JAHA). Led by principal investigator Raphael Schiffmann, MD, (Director of Baylor's Institute for Metabolic Disease, part of Baylor Research Institute), the study found that patients with a higher level of the urinary lipid globotriaosylceramide (Gb3) may be at greater risk for near-term death as a result of heart disease. The presence of elevated urinary Gb3, along with other lipids, indicated for the first time that heart disease is linked to lipid abnormalities in organs outside of the heart in patients with common forms of heart disease.

Hey, check out all the engineering jobs. Post your resume today!

Back to news